In a previous blog posted on April 16, 2026 (here), we discussed the announcement from FDA regarding an upcoming meeting of the Pharmacy Compounding Advisory Committee to be held on July 23-24, 2026, focused on the inclusion of some active ingredients on the permitted pharmacy compounding list. That post identified seven peptide active ingredients that the Agency would consider as part of its evaluation.
Well, that meeting is coming close and FDA has released its background materials (here) in advance of the meeting and the results are not favorable for inclusion of the proposed peptides on that list. In general, according to the FDA’s background materials, the Agency has found limited evidence supporting the safety or efficacy of the peptide ingredients proposed for inclusion on the list of active ingredients available for use in pharmacy compounding.
While the meeting is advisory in nature and no final decision will be made at the meeting, the tenor of the scientific evaluation in its briefing documents does not seem to bode well to receive an “OK” for inclusion on the list. As noted in my previous post linked above, I raise the question that with the FDA’s previously expressed concerns about some of these drug substances, the question is, what may have changed so dramatically? The answer may be nothing!
